title: Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments.
abstract: Until 2010, chemotherapy with docetaxel was the only approved agent for treatment of metastatic castrate resistant prostate cancer (mCRPC). Since then, the therapeutic landscape of mCRPC has changed rapidly. Multiple novel agents have received regulatory approval after demonstrating improved overall survival in separate randomized Phase 3 studies. These include immunotherapeutic agent sipuleucel-T, androgen axis inhibitors abiraterone and enzalutamide, and a novel microtubule inhibitor cabazitaxel. More recently, radium-223, a bone-targeting alpha emitting radiopharmaceutical, was reported to improve skeletal related events, as well as overall survival in a Phase 3 randomized study. Additionally, there are several promising agents in the advanced stages of clinical development. Here, we describe the agents recently shown to improve overall survival, and those that have reached the advanced stages of development in Phase 3 clinical trials. We will also propose a strategy for optimal sequencing of these agents in the treatment of mCRPC.
authors.affiliation: University of Utah, Huntsman Cancer Institute, 2000 Circle of Hope, Ste 2123, Salt Lake City, UT 84112, USA.
authors.forename: Tian Yi
authors.initials: TY
authors.lastname: Zhang
authors.forename: Neeraj
authors.initials: N
authors.lastname: Agarwal
authors.forename: Guru
authors.initials: G
authors.lastname: Sonpavde
authors.forename: Giuseppe
authors.initials: G
authors.lastname: DiLorenzo
authors.forename: Joaquim
authors.initials: J
authors.lastname: Bellmunt
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Vogelzang
mesh_terms: D000736:Androstenes; D000737:Androstenols / Q000008:administration & dosage; D000813:Anilides / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D018572:Disease-Free Survival; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D000074324:Ipilimumab; D008297:Male; D009281:Naphthalenes / Q000008:administration & dosage; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000008:administration & dosage / Q000031:analogs & derivatives; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000473:pathology; D011725:Pyridines / Q000008:administration & dosage; D011804:Quinolines / Q000008:administration & dosage; D015363:Quinolones; D011868:Radioisotopes / Q000008:administration & dosage; D011883:Radium / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage; D013873:Thionucleotides / Q000008:administration & dosage; D014020:Tissue Extracts / Q000008:administration & dosage
chemical_list: D000736:Androstenes; D000737:Androstenols; D000813:Anilides; D000911:Antibodies, Monoclonal; D001549:Benzamides; D007093:Imidazoles; D000074324:Ipilimumab; D009281:Naphthalenes; D009570:Nitriles; C503781:OGX-011; D011725:Pyridines; D011804:Quinolines; D015363:Quinolones; D011868:Radioisotopes; D043823:Taxoids; D013873:Thionucleotides; D014020:Tissue Extracts; C558660:cabozantinib; D010669:Phenylthiohydantoin; C552428:cabazitaxel; C516109:tasquinimod; C511774:sipuleucel-T; C540278:enzalutamide; C089740:abiraterone; C581106:radium Ra 223 dichloride; C571806:orteronel; D011883:Radium
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: BMC Mol Biol. 2013 Feb 16;14:6
references.pmid: 23414343
references.citation: J Biomed Biotechnol. 2010;2010:
references.pmid: 20706612
references.citation: Expert Opin Biol Ther. 2007 Aug;7(8):1245-56
references.pmid: 17696822
references.citation: Lancet. 2010 Oct 2;376(9747):1147-54
references.pmid: 20888992
references.citation: Nature. 2012 Jul 12;487(7406):239-43
references.pmid: 22722839
references.citation: BMC Cancer. 2010 Oct 14;10:556
references.pmid: 20946682
references.citation: Semin Oncol. 2005 Dec;32(6):549-55
references.pmid: 16338420
references.citation: Eur Urol. 2013 Feb;63(2):198-200
references.pmid: 23062225
references.citation: Science. 2009 May 8;324(5928):787-90
references.pmid: 19359544
references.citation: Clin Cancer Res. 2011 Sep 15;17(18):5913-25
references.pmid: 21807635
references.citation: N Engl J Med. 2013 Jan 10;368(2):138-48
references.pmid: 23228172
references.citation: J Clin Oncol. 2013 Feb 1;31(4):412-9
references.pmid: 23169517
references.citation: Eur Urol. 2012 May;61(5):950-60
references.pmid: 22209376
references.citation: J Clin Oncol. 2010 Oct 10;28(29):e560-1; author reply e562
references.pmid: 20805462
references.citation: Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1643-8
references.pmid: 22307624
references.citation: Cancer Res. 2013 Feb 15;73(4):1386-99
references.pmid: 23149916
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: N Engl J Med. 1989 Aug 17;321(7):419-24
references.pmid: 2503724
references.citation: J Clin Oncol. 2010 Sep 20;28(27):4247-54
references.pmid: 20733135
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1099-105
references.pmid: 20100959
references.citation: N Engl J Med. 2011 May 26;364(21):1995-2005
references.pmid: 21612468
references.citation: Nat Rev Urol. 2010 Sep;7(9):494-509
references.pmid: 20818327
references.citation: N Engl J Med. 2004 Oct 7;351(15):1513-20
references.pmid: 15470214
references.citation: Clin Cancer Res. 2007 Feb 1;13(3):958-64
references.pmid: 17289891
references.citation: Clin Cancer Res. 2010 Feb 15;16(4):1088-93
references.pmid: 20145158
references.citation: N Engl J Med. 2004 Oct 7;351(15):1502-12
references.pmid: 15470213
references.citation: J Clin Oncol. 2011 Oct 20;29(30):4022-8
references.pmid: 21931019
references.citation: Nat Rev Immunol. 2010 Aug;10(8):580-93
references.pmid: 20651745
references.citation: J Clin Oncol. 2012 Feb 20;30(6):644-6
references.pmid: 22184375
references.citation: Expert Opin Investig Drugs. 2010 Oct;19(10):1235-43
references.pmid: 20836618
references.citation: PLoS One. 2012;7(3):e34207
references.pmid: 22470535
references.citation: Lancet Oncol. 2012 Oct;13(10):983-92
references.pmid: 22995653
references.citation: Clin Genitourin Cancer. 2012 Jun;10(2):84-92
references.pmid: 22409862
references.citation: N Engl J Med. 2010 Jul 29;363(5):411-22
references.pmid: 20818862
references.citation: N Engl J Med. 2012 Sep 27;367(13):1187-97
references.pmid: 22894553